<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.4 20241031//EN" "JATS-archivearticle1-4-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.4" xml:lang="en" article-type="research-article"><?properties manuscript?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-journal-id">101233132</journal-id><journal-id journal-id-type="pubmed-jr-id">36856</journal-id><journal-id journal-id-type="nlm-ta">Nanotoxicology</journal-id><journal-id journal-id-type="iso-abbrev">Nanotoxicology</journal-id><journal-title-group><journal-title>Nanotoxicology</journal-title></journal-title-group><issn pub-type="ppub">1743-5390</issn><issn pub-type="epub">1743-5404</issn></journal-meta><article-meta><article-id pub-id-type="pmid">41505901</article-id><article-id pub-id-type="pmc">13313775</article-id><article-id pub-id-type="doi">10.1080/17435390.2025.2610342</article-id><article-id pub-id-type="manuscript">HHSPA2176311</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Lipidomics analysis reveals signature inflammatory and specialized pro-resolving mediators at the junction of inflammation-resolution transition in mouse lungs exposed to multiwalled carbon nanotubes</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Qiang</given-names></name><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Lim</surname><given-names>Chol Seung</given-names></name><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>LeBouf</surname><given-names>Ryan F.</given-names></name><xref rid="A2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Rimayi</surname><given-names>Chengetayi Cornelius</given-names></name><xref rid="A2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Ju-Hyeong</given-names></name><xref rid="A2" ref-type="aff">b</xref></contrib></contrib-group><aff id="A1"><label>a</label>Receptor Biology Laboratory, Toxicology and Molecular Biology Branch, Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Morgantown, WV, USA</aff><aff id="A2"><label>b</label>Field Studies Branch, Respiratory Health Division, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Morgantown, WV, USA</aff><author-notes><corresp id="CR1"><bold>CONTACT</bold> Qiang Ma, <email>qam1@cdc.gov</email>, Toxicology and Molecular Biology Branch, Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, 1000 Frederick Lane, Morgantown, WV 26508, USA</corresp><fn fn-type="con" id="FN1"><p id="P1">Author contributions</p><p id="P2">Q.M. and R.F.L conceived the study; Q.M., C.S.L., R.F.L., C.C.R., and J.H.P. designed the study, provided reagents, and performed experiments; Q.M. and C.S.L. performed data analysis and statistical analysis; Q.M. wrote the manuscript. All authors contributed to manuscript preparation and finalization.</p></fn></author-notes><pub-date pub-type="nihms-submitted"><day>28</day><month>5</month><year>2026</year></pub-date><pub-date pub-type="ppub"><season>Feb-Mar</season><year>2026</year></pub-date><pub-date pub-type="epub"><day>08</day><month>1</month><year>2026</year></pub-date><pub-date pub-type="pmc-release"><day>29</day><month>6</month><year>2026</year></pub-date><volume>20</volume><issue>1-2</issue><fpage>1</fpage><lpage>17</lpage><permissions><license><license-p>This work was authored as part of the Contributor&#x02019;s official duties as an Employee of the United States Government and is therefore a work of the United States Government. In accordance with 17 U.S.C. 105, no copyright protection is available for such works under U.S. Law.</license-p></license></permissions><abstract id="ABS1"><p id="P3">Pulmonary exposure to certain multiwalled carbon nanotubes (MWCNTs) triggers significant inflammation that is regulated temporally by powerful mediators of inflammation and resolution. Among these mediators, inflammatory lipid mediators (ILMs) and specialized pro-resolving mediators (SPMs) have garnered increasing attention. In this study, lipidomics analysis revealed that fibrogenic MWCNTs stimulate the production of signature ILMs and SPMs in mouse lungs, marking a phenotypic shift from acute inflammation to resolution. Mice exposed to 40 &#x003bc;g MWCNTs via oropharyngeal aspiration exhibited dynamic, polarized pulmonary inflammation. By day 7 post-exposure, lung tissue showed elevated M2 macrophage markers and cytokines, with lesions characterized by moderate neutrophil infiltration and a marked increase in macrophages within alveolar sacs and interstitial spaces. These macrophages contained engulfed nanoparticles and formed clusters of varying sizes. In vitro, MWCNTs promoted nanoparticle phagocytosis and cytoplasmic phospholipid accumulation. Lipidomics profiling of lung bioactive lipids, performed using ultraperformance liquid chromatography-tandem mass spectrometry, showed significant increases in ILMs and SPMs. These included prostaglandin (PG) E2, PGD2, thromboxane B2, leukotriene B4, and lipoxin B4 from the arachidonic acid pathway; resolvin (Rv) D5, protectin DX, maresin 1, 17-hydroxydocosahexaenoic acid (HDHA), and 14S-HDHA from the docosahexaenoic acid pathway; and RvE2, 15-hydroxyeicosapentaenoic acid (HEPE), and 18-HEPE from the eicosapentaenoic acid pathway. These findings suggest that MWCNTs trigger a distinct lipid mediator signature at the junction of inflammation-resolution transition to promote the programmatic switch from acute inflammation to resolution, supporting continued particle clearance, inflammation resolution, and return to homeostasis in response to nanoparticle exposure.</p></abstract><kwd-group><kwd>MWCNT</kwd><kwd>lipidomics</kwd><kwd>lung inflammation</kwd><kwd>resolution of inflammation</kwd><kwd>fibrosis</kwd></kwd-group></article-meta></front><body><sec id="S1"><title>Introduction</title><p id="P4">Pulmonary inflammation is a common and often prominent acute response to inhaled particles and nanoparticles, provided that the dose is sufficient relative to the potency of the particles (<xref rid="R16" ref-type="bibr">Ma 2020</xref>). While acute inflammation facilitates the clearance of inhaled particles, it can also cause damage to lung tissue due to the release of potent, cell-killing molecules from neutrophils and macrophages. Timely resolution of inflammation is crucial for recovery and the maintenance of tissue structure and function following exposure to a stimulus (<xref rid="R25" ref-type="bibr">Serhan and Savill 2005</xref>).</p><p id="P5">The initiation and resolution of inflammation are regulated by potent lipid mediators (LMs), which can either augment inflammation or promote the resolution of inflammation (<xref rid="R23" ref-type="bibr">Ricciotti and FitzGerald 2011</xref>, <xref rid="R1" ref-type="bibr">Chiang and Serhan 2020</xref>). Failure of resolution of inflammation leads to chronicity and adverse disease outcomes. In this connection, inflammatory lipid mediators (ILMs) recruit leukocytes and activate neutrophils and macrophages, both of which are critical for initiating and amplifying acute inflammation. ILMs include prostaglandins (PGs), thromboxane (TX), and leukotrienes (LTs), all derived from arachidonic acid (AA) through the cyclooxygenase (COX) and arachidonate 5-lipoxygenase (Alox5) pathways. On the other hand, specialized pro-resolving mediators (SPMs) are produced to actively halt inflammation and promote tissue regeneration (<xref rid="R1" ref-type="bibr">Chiang and Serhan 2020</xref>). SPMs include lipoxins (LXs) generated from AA, D-series resolvins (RvDs), protectins, and maresins (MaRs) derived from docosahexaenoic acid (DHA), as well as E-series resolvins (RvEs) from eicosapentaenoic acid (EPA). While AA is a &#x003c9;-6 polyunsaturated fatty acid (PUFA) synthesized de novo in the human body, DHA and EPA are &#x003c9;-3 PUFAs primarily obtained from dietary sources.</p><p id="P6">Multiwalled carbon nanotubes (MWCNTs) are carbon allotropes composed of multiple concentric cylindrical layers formed by graphene-like sheets. These sheets consist of carbon atoms arranged in hexagonal lattices through sp<sup>2</sup> hybridization (<xref rid="R28" ref-type="bibr">Sinnott and Andrews 2001</xref>). MWCNTs possess excellent tensile strength, electrical conductivity, and thermal and optical properties, making them of particular interest for various industrial and commercial applications (<xref rid="R2" ref-type="bibr">De Volder et al. 2013</xref>, <xref rid="R32" ref-type="bibr">Zhang et al. 2013</xref>, <xref rid="R12" ref-type="bibr">Hughes et al. 2024</xref>). However, due to their airborne nature and resistance to degradation, there are concerns regarding potential long-lasting health effects when inhaled by workers and consumers (<xref rid="R3" ref-type="bibr">Donaldson et al. 2006</xref>, <xref rid="R19" ref-type="bibr">NIOSH. 2013</xref>, <xref rid="R8" ref-type="bibr">Dong and Ma 2019</xref>). Toxicological studies in laboratory animals have shown that certain MWCNTs can induce lung inflammation and other lesions with potencies comparable to those of respirable mineral particles and fibers known to cause lung fibrosis and cancer in humans, such as silica and asbestos (<xref rid="R21" ref-type="bibr">Porter et al. 2010</xref>, <xref rid="R18" ref-type="bibr">Mercer et al. 2013</xref>, <xref rid="R4" ref-type="bibr">Dong and Ma 2015</xref>, <xref rid="R9" ref-type="bibr">Dong et al. 2015</xref>, <xref rid="R30" ref-type="bibr">Suzui et al. 2016</xref>).</p><p id="P7">MWCNT-induced lung inflammation exhibits polarized, biphasic responses (<xref rid="R7" ref-type="bibr">Dong and Ma 2018a</xref>, <xref rid="R16" ref-type="bibr">Ma 2020</xref>). The early phase is characterized by type 1 inflammation, marked by rapid neutrophil infiltration, high levels of proinflammatory cytokines, and phagocytosis of particles by classically activated (M1) macrophages (<xref rid="R21" ref-type="bibr">Porter et al. 2010</xref>, <xref rid="R9" ref-type="bibr">Dong et al. 2015</xref>). Neutrophil infiltration peaks at 1-day post-exposure, while M1 macrophage accumulation peaks at 3-days post-exposure. Following this initial response, neutrophils are rapidly cleared from inflammatory sites, and macrophages continue to accumulate, adopting the phenotypes of alternatively activated (M2) macrophages, which are key mediators of type 2 inflammation. This type 2 inflammation is characterized by the resolution of inflammation and fibroproliferation, leading either to tissue repair and recovery or to chronic outcomes such as fibrosis (<xref rid="R5" ref-type="bibr">Dong and Ma 2016</xref>, <xref rid="R6" ref-type="bibr">Dong and Ma 2018b</xref>, <xref rid="R14" ref-type="bibr">Lim et al. 2020</xref>).</p><p id="P8">The time-dependent polarization of lung macrophages into M1 and M2 states is critical for the regulation of particle- and nanoparticle-induced lung inflammation through ILMs and SPMs. In this context, the phagocytosis of particles activates the COX- and Alox5-dependent pathways to produce inflammatory prostanoids and leukotrienes in M1 macrophages (<xref rid="R14" ref-type="bibr">Lim et al. 2020</xref>, <xref rid="R13" ref-type="bibr">Lim et al. 2023</xref>, <xref rid="R15" ref-type="bibr">Lim, Gu, and Ma 2025</xref>), whereas tissue damage caused by particle depositition and inflammation over time stimulates the synthesis and secretion of SPMs from DHA, EPA, and AA through Alox5- and Alox15-dependent pathways to mediate resolution of lung inflammation (<xref rid="R14" ref-type="bibr">Lim et al. 2020</xref>).</p><p id="P9">The significant role of ILMs and SPMs in inflammation and its resolution has generated considerable interest in understanding their functions and regulation during the temporal evolution and outcomes of lung inflammation induced by particles and nanoparticles. Fibrogenic MWCNTs have been shown to stimulate the production of ILMs, such as PGE2 and LTB4, in mouse lungs and bronchoalveolar lavage fluid (BALF) during acute inflammation, as well as SPMs, such as LXs and RvDs, in later phases of inflammation (<xref rid="R14" ref-type="bibr">Lim et al. 2020</xref>). MWCNTs have also been found to induce the expression of the Cox-2 enzyme in allergen and MWCNT-stimulated airway remodeling in mice (<xref rid="R24" ref-type="bibr">Sayers et al. 2013</xref>). Given the complexity of the networks formed by ILMs and SPMs, we recently developed a method using ultraperformance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) that, when combined with a C18 spin column solid phase extraction, enabled efficient lipidomics profiling of LMs in mouse lungs during acute inflammation induced by fibrogenic MWCNTs (<xref rid="R17" ref-type="bibr">Ma et al. 2025</xref>).</p><p id="P10">Considering the polarized and biphasic nature of MWCNT-induced lung inflammation, we hypothesize that MWCNTs stimulate the synthesis of SPMs during the transition from neutrophil-predominant type 1 inflammation to macrophage-predominant type 2 inflammation, thereby promoting the resolution of inflammation. In this study, we performed lipidomics profiling of ILMs and SPMs at 7 days post-exposure to MWCNTs, a time point at which acute inflammation is expected to transition to resolution or chronic progression (<xref rid="R5" ref-type="bibr">Dong and Ma 2016</xref>, <xref rid="R6" ref-type="bibr">2018b</xref>). Our findings indicate that MWCNTs induced macrophage-predominant inflammation in mouse lungs during the transition. We observed that MWCNTs stimulated the phagocytosis of particles by macrophages and the accumulation of phospholipids in the cytoplasm <italic toggle="yes">in vitro</italic>. Lipidomics profiling revealed that MWCNTs increased the production of ILMs, including PGH2, PGE2, PGD2, TXB2, and LTB4, as well as SPMs, including LXB4, RvD5, RvE4, MaR1, and PDX, a signature of LMs that facilitate the continued clearance of particles and the resolution of sterile inflammation in mouse lungs exposed to fibrogenic MWCNTs.</p></sec><sec id="S2"><title>Materials and methods</title><sec id="S3"><title>MWCNTs and preparation</title><p id="P11">MWCNTs used in this study were sourced from Mitsui &#x00026; Company (Mitsui-7, XNRI 1, lot #05072001K28, Tokyo, Japan). MWCNTs were imaged using transmission electron microscopy (TEM), as described in our previous publication (<xref rid="R13" ref-type="bibr">Lim et al. 2023</xref>). Stock samples prepared as described below were further diluted in double distilled H<sub>2</sub>O to 1:300 for most of the samples. One drop of the diluted samples was placed onto a formvar-coated 200 mesh copper grid and allowed to dry overnight. The samples were imaged using a JEOL 1400 TEM (Tokyo, Japan) at 80 kV. For MWCNTs, length measurements were taken from the longest straight distance between two points. The width measurement was the distance perpendicular to the structural walls of the CNTs.</p><p id="P12">The MWCNTs have a log-normal length distribution with a mean length of 4.46 &#x003bc;m (95% confidence interval: 4.08&#x02013;4.88 &#x003bc;m) and a normal width distribution with a mean of 58.5 nm (95% confidence interval: 56.0&#x02013;61.0 nm). The MWCNTs are rod-like fibers (<xref rid="F1" ref-type="fig">Figure 1(A)</xref>) with a surface area of 26 m<sup>2</sup>/g, containing low levels of trace elements (0.78% for all metals and 0.32% for iron) (<xref rid="R21" ref-type="bibr">Porter et al. 2010</xref>). The level of lipopolysaccharides in the MWCNTs was determined to be &#x0003c;0.01 mg/mL or &#x0003c;0.1 EU/mL using the Pierce LAL chromogenic endotoxin quantification kit (Thermo Fisher Scientific, Pittsburgh, PA).</p><p id="P13">For animal treatment, MWCNTs were prepared as described previously (<xref rid="R21" ref-type="bibr">Porter et al. 2010</xref>, <xref rid="R14" ref-type="bibr">Lim et al. 2020</xref>). The dispersion medium (DM) consisted of 0.9% saline, 0.6 mg/mL mouse serum albumin (Millipore Sigma, Burlington, MA, USA), and 0.01 mg/mL 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (Millipore Sigma). MWCNTs were suspended in DM following a two-step dispersion procedure involving sonication. DM was also used as the vehicle control for MWCNTs in animal experiments. For cell culture treatment, MWCNTs were suspended in Dulbecco&#x02019;s Modified Eagle&#x02019;s Medium (DMEM, Thermo Fisher Scientific) containing 1% fetal bovine serum (FBS, Thermo Fisher Scientific) using vortexing and sonication. The DMEM with 1% FBS served as the vehicle control for MWCNTs in cell culture.</p></sec><sec id="S4"><title>Animals and treatment</title><p id="P14">Adult male C57BL/6J mice were obtained from the Jackson Laboratories (Bar Harbor, ME, USA) and housed in an accredited, specific pathogen-free, and environmentally controlled facility at the National Institute for Occupational Safety and Health. The mice were kept in polycarbonate ventilated cages with HEPA-filtered air and maintained on a 12-hour fluorescent lighting schedule. They were provided with Harlan Teklad Rodent Diet 7913 (Indianapolis, IN, USA) and tap water <italic toggle="yes">ad libitum</italic>. All animal experiments were conducted in accordance with humane care guidelines and were approved by the Institutional Animal Care and Use Committee.</p><p id="P15">Mice were treated with a single dose of MWCNTs (40 &#x003bc;g/mouse, adjusted to body weight) or vehicle control (dispersion medium, DM, 50 &#x003bc;L/mouse, adjusted to body weight) via oropharyngeal aspiration. Euthanasia was performed using an intraperitoneal injection of a sodium pentobarbital euthanasia solution (100&#x02013;300 mg/kg body weight; Zoetis, Florham Park, NJ, USA), followed by exsanguination once the mouse became unresponsive to toe pinch.</p><p id="P16">Oropharyngeal aspiration is a noninvasive route of administration to deliver a specific dose of respirable materials, such as nanoparticles, into animal lungs to result in an even distribution of the materials in the lungs (<xref rid="R22" ref-type="bibr">Rao et al. 2003</xref>). MWCNTs at 40 &#x003bc;g in 50 &#x003bc;L DM administered by aspiration induced rapid and pronounced acute inflammation in mouse lungs, characterized by significant neutrophil infiltration and the secretion of proinflammatory cytokines (<xref rid="R21" ref-type="bibr">Porter et al. 2010</xref>, <xref rid="R9" ref-type="bibr">Dong et al. 2015</xref>, <xref rid="R14" ref-type="bibr">Lim et al. 2020</xref>). At nearly equivalent lung burdens of the MWCNTs, lung inflammation on day 1 post-exposure was similar between a single dose exposure by aspiration at a dose of 80 &#x003bc;g/mouse and by aerosol inhalation at 5 mg/m<sup>3</sup>, 5 hours/day, 12 days (<xref rid="R18" ref-type="bibr">Mercer et al. 2013</xref>). This inhalation paradigm results in a lung burden in mice equal to a predicted human lung burden on an equivalent alveolar surface area basis for a person performing light work at 7 &#x003bc;g/m<sup>3</sup> for 13 years. These MWCNTs at 40 or 80 &#x003bc;g were shown to produce comparable pulmonary effects (<xref rid="R21" ref-type="bibr">Porter et al. 2010</xref>). Thus, a dose of the MWCNTs at 40 or 80 &#x003bc;g by aspiration in mice would produce an initial lung burden in humans comparable to that by inhalation.</p><p id="P17">There has been a paucity of data on human exposure to engineered nano materials. It has been estimated that this dose of 40 &#x003bc;g MWCNT exposure in mice approximates human deposition for a person performing light work for 11 years (<xref rid="R14" ref-type="bibr">Lim et al. 2020</xref>). This estimation assumes that a worker performs light work in an environment with MWCNT aerosol of 10.6 mg/m<sup>3</sup> (<xref rid="R10" ref-type="bibr">Erdely et al. 2013</xref>) and has a minute ventilation of 20 L/min (<xref rid="R11" ref-type="bibr">Galer et al. 1992</xref>), a deposition fraction of 30% (<xref rid="R20" ref-type="bibr">Phalen 2008</xref>), and an alveolar epithelium surface area of 102 m<sup>2</sup> (<xref rid="R29" ref-type="bibr">Stone et al. 1992</xref>), which gives an estimated human exposure per year of 7.3 mg/m<sup>2</sup> alveolar epithelium.</p></sec><sec id="S5"><title>Animal lung collection, histology, and immunohistochemistry</title><p id="P18">After euthanasia, mouse lungs were collected from four mice each group for analysis. The right lung lobes were minced, frozen in liquid nitrogen, and stored at &#x02212;80 &#x000b0;C for lipidomics and protein analyses. The left lungs were formalin-fixed, paraffin-embedded, and sectioned to 5 microns. Lung sections were stained using hematoxylin-eosin (H&#x00026;E) staining or Masson&#x02019;s trichrome staining (MTS) following standard procedures.</p><p id="P19">For immunohistochemistry, lung sections were deparaffinized with three washes of xylene (5 minutes each), rehydrated with two washes of 100% ethanol (10 minutes each), two washes of 95% ethanol (10 minutes each), and one wash of 70% ethanol (5 minutes), followed by two washes with deionized water (5 minutes each). To unmask antigens, sections were heated in a 10 mM sodium citrate buffer (pH 6.0) at sub-boiling temperature (10 minutes) in a microwave oven, followed by cooling on a benchtop for 30 minutes. The slides were then incubated with a BLOXALL endogenous peroxidase and alkaline phosphatase blocking solution (Vector Laboratories, Burlingame, CA, USA) for 10 minutes. Immunohistochemistry was performed using the ImmPRESS polymer detection system (Vector Laboratories) with ImmPACT NovaRED as a peroxidase substrate (red in color). Nuclei were counterstained with hematoxylin OS (blue violet in color, Vector Laboratories). Primary antibodies used included anti-Mac2 for macrophage detection (Cedarlane, Burlington, Ontario, Canada) and anti-neutrophil for neutrophil detection (Abcam, Cambridge, MA, USA). Images were captured using an Olympus Provis AX-70 microscope (Olympus, Center Valley, PA, USA). Positively stained cells were counted from five images taken at 40x magnification from one section, and lung sections from four mice in each group were examined.</p></sec><sec id="S6"><title>Cell culture and detection of phospholipids</title><p id="P20">J774A.1 murine monocyte/macrophage cell line was obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were cultured in DMEM with 10% FBS in a cell culture incubator at 37 &#x000b0;C with 5% CO<sub>2</sub>. J774A.1 cells are known to avidly phagocytose nanoparticles and secrete significant amounts of proinflammatory cytokines, such as interleukin (IL)-1&#x003b2; and tumor necrosis factor (TNF)-&#x003b1;, in response to nanoparticle exposure, mirroring the behavior of mouse alveolar macrophages (<xref rid="R14" ref-type="bibr">Lim et al. 2020</xref>, <xref rid="R13" ref-type="bibr">Lim et al. 2023</xref>, <xref rid="R15" ref-type="bibr">Lim, Gu, and Ma 2025</xref>).</p><p id="P21">Cells were plated on a 24-well plate overnight, followed by treatment with vehicle control or MWCNTs at a concentration of 2 &#x003bc;g/mL for 24 hours. At this dose, MWCNTs induce prominent proinflammatory responses in J774A.1 macrophage cells (<xref rid="R14" ref-type="bibr">Lim et al. 2020</xref>, <xref rid="R13" ref-type="bibr">Lim et al. 2023</xref>). After treatment, the cells were stained with the LipidTox Red Phospholipidosis reagent (LTRP, Thermo Fisher Scientific) for an additional 24 hours under the same culture conditions before fixation with 3.7% formaldehyde. The nuclei were counterstained using 4&#x02032;,6-diamidino-2-phenylindole (DAPI, Thermo Fisher Scientific). Images were captured using the Agilent BioTek Cytation 1 Cell Imaging Multi-Mode Reader (Model CYT1FAV, Agilent, San Diego, CA, USA), utilizing phase contrast for optical morphology, a DAPI filter for DAPI fluorescence (EX 360 nm, EM 460 nm), and a TRITC filter for LTRP fluorescence (EX 595 nm, EM 615 nm). Scale bars were set at 200 &#x003bc;m. Images were analyzed for relative fluorescence intensity (RFU) using the Gen5 software (Agilent). Data were presented as mean &#x000b1; SD from four separate cell populations.</p></sec><sec id="S7"><title>UPLC&#x02013;MS/MS chemicals</title><p id="P22">All chemicals used for UPLC&#x02013;MS/MS analysis were of LCMS grade and obtained from Fisher Scientific (Pittsburgh, PA, USA). Methanol and acetonitrile were &#x0003e;99.9% pure, and acetic acid was 99.9% pure. Ultrapure water was prepared using a Millipore LC pak polisher cartridge with a Millipak Express Filter MPGP04001 (Millipore Sigma).</p></sec><sec id="S8"><title>Lipidomics standards for LMs</title><p id="P23">A total of 36 target standards and five deuterium-labeled internal standards were utilized for the calibration and quantification of LMs, as described previously (<xref rid="R17" ref-type="bibr">Ma et al. 2025</xref>). The standards were sourced from Cayman Chemicals (Ann Arbor, MI, USA) and had purities of &#x02265;98%. Each sample was spiked with 100 pg/mL of the internal standards. Calibration standards for the target LMs were prepared across two ranges to accommodate varying levels of endogenous LMs in samples. The linear calibration range was from 0.66 pg/&#x003bc;L to 675 pg/&#x003bc;L for most LMs, while EPA, AA, and DHA had a range of 0.82 pg/&#x003bc;L to 13,500 pg/&#x003bc;L. The limit of detection (LOD) and limit of quantitation (LOQ) were calculated at 3&#x000d7; and 10&#x000d7; the signal-to-noise ratio, respectively.</p><p id="P24">The 36 target standards included various hydroxyeicosatetraenoic acids (HETEs), resolvins, lipoxins (LXs), prostaglandins (PGs), protectins, and thromboxane (TX). The specific compounds analyzed were: 5-hydroxyeicosapentaenoic acid (5-HEPE), 5-hydroxyeicosatetraenoic acid (5-HETE), 12-hydroxyeicosapentaenoic acid (12-HEPE), 12-hydroxyeicosatetraenoic acid (12-HETE), 14S-hydroxyhexaenoic acid (14S-HDHA), 15-hydroxyeicosapentaenoic acid (15-HEPE), 15-hydroxyeicosatetraenoic acid (15-HETE), 15R-lipoxin A4 (15R-LXA4), 17-hydroxyhexaenoic acid (17-HDHA), 17R-resolvin D1 (17R-RvD1), 17R-resolvin D4 (17R-RvD4), 18-hydroxyeicosapentaenoic acid (18-HEPE), arachidonic acid (AA), docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), leukotriene B4 (LTB4), lipoxin A4 (LXA4), lipoxin A5 (LXA5), lipoxin B4 (LXB4), maresin 1 (MaR1), maresin 2 (MaR2), prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), prostaglandin F2&#x003b1; (PGF2&#x003b1;), prostaglandin H2 (PGH2), protectin D1 (PD1), protectin DX (PDX), resolvin D1 (RvD1), resolvin D2 (RvD2), resolvin D3 (RvD3), resolvin D4 (RvD4), resolvin D5 (RvD5), resolvin E1 (RvE1), resolvin E2 (RvE2), resolvin E4 (RvE4), and thromboxane B2 (TXB2).</p><p id="P25">The five deuterium-labeled internal standards included: 5S-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic-5,6,8, 9,11,12,14,15-d8 acid (5S-HETE-d8), 5S,12R-dihydroxy-6Z, 8E,10E,14Z-eicosatetraenoic-6,7,14,15-d4 acid (LTB4-d4), 5S,6R,15S-trihydroxyicosa-7E,9E,11Z,13E-tetraenoic-19,19,20,20,20-d5 acid (LXA4-d5), 9-oxo-11&#x003b1;,15S-dihydroxy-prosta-5Z,13E-dien-1-oic-3,3,4,4-d4 acid (PGE2-d4), and 7S,16R,17S-trihydroxy-4Z,8E,10Z,12E,14E,19Z-21,21&#x02032;,22,22,2 2-d5 docosahexaenoic acid (RvD2-d5).</p></sec><sec id="S9"><title>Sample preparation for liquid chromatography</title><p id="P26">Mouse lung tissue samples (four mice each group) were homogenized in ice-cold methanol (375 &#x003bc;L, LCMS grade, Fisher Scientific) spiked with 25 &#x003bc;L of the internal standards mixture using a Dounce homogenizer. The homogenates were incubated at &#x02212;20 &#x000b0;C for 30 minutes, followed by centrifugation at 751 &#x000d7; g for 10 minutes to obtain supernatants. The supernatants were then acidified to pH 3.5.</p></sec><sec id="S10"><title>Solid phase extraction</title><p id="P27">Lipids were extracted using solid-phase extraction with a C18 spin column (BioPureSPN Midi PROTO 300 C18, 17&#x02013;170 mg, P/N HEM S18V) obtained from the Nest Group (Ipswich, MA, USA). Briefly, sample extracts were evaporated under a gentle stream of nitrogen using a TurboVap (Zymark, Hopkinton, USA) and reconstituted in 250 &#x003bc;L of a Milli-Q water:methanol mixture (80:20, v/v) with vortexing for 15 seconds. The reconstituted sample was added to a pre-conditioned C18 spin column, followed by pulse-spin at up to 1500 &#x000d7; g to remove the flow-through. The C18 column was washed with two volumes of 250 &#x003bc;L Milli-Q water:methanol (80:20, v/v). Lipids were then eluted by adding 250 &#x003bc;L of acetonitrile:Milli-Q water (80:20, v/v) on top of the C18 sorbent, followed by pulse-spin centrifugation past 1500 &#x000d7; g. The eluent was collected in a 1.5 mL centrifuge tube and evaporated to dryness using the TurboVap under a gentle nitrogen stream at 47 &#x000b0;C. The dried eluent was reconstituted in 45 &#x003bc;L of a mobile phase solvent mixture (A: B, 1:1, v/v) for immediate LC-MS/MS analysis, along with freshly prepared calibration internal standards.</p></sec><sec id="S11"><title>Ultraperformance liquid chromatography (UPLC)</title><p id="P28">A liquid chromatography-tandem quadrupole mass spectrometer (Waters ACQUITY Xevo TQ-XS UPLC-MS, Waters, Milford, MA, USA) was utilized for lipidomic analysis (<xref rid="R17" ref-type="bibr">Ma et al. 2025</xref>). The Acquity Premier UPLC system was operated with an ACQUITY Premier HSS T3 column (1.8 &#x003bc;m, 2.1 &#x000d7; 100 mm, Product number 186009471, Waters) using a 10 &#x003bc;L injection volume. The column and sample tray temperatures were maintained at 50 &#x000b0;C and 4 &#x000b0;C, respectively, throughout the chromatographic runs. The mobile phase gradient consisted of solvent A (95% Milli-Q ultrapure water, 5% methanol, and 0.01% acetic acid with 10 mM ammonium acetate) and solvent B (95% methanol, 5% Milli-Q ultrapure water, and 0.01% acetic acid with 10 mM ammonium acetate). The flow rate was set to 200 &#x003bc;L/min. The gradient began with 100% solvent A and 0% solvent B, gradually increasing solvent B to 70% over 17 minutes. Solvent B was then increased to 85% over three minutes (from 17 to 20 minutes) and to 100% at 25 minutes, where it was held for 2 minutes. For re-equilibration, solvent B was reduced to 0% from 27 to 28 minutes and held for an additional 2.5 minutes. The total running time for each cycle was 30.5 minutes.</p></sec><sec id="S12"><title>Mass spectrometry parameters and transitions</title><p id="P29">The tandem quadrupole mass spectrometer (Waters Xevo TQ-XS) was operated with an electrospray ionization (ESI) source in negative-ionization mode for the analysis of target analytes. The instrument was set with an ESI capillary voltage of 1.5 kV, and the source and desolvation temperatures were maintained at 150 &#x000b0;C and 250 &#x000b0;C, respectively. High-purity nitrogen (Peak Scientific Instruments, Westford, MA, USA) was used with desolvation and cone gas flow rates of 600 and 150 L/hour, respectively. The collision cell entrance and exit potentials were both set to 30 V. The system operated in multiple reaction monitoring (MRM) mode, with 4 to 5 optimized transitions for each compound, except for 12-HEPE, which had 2 reliable transitions optimized and used. The cone voltage and collision energy were individually optimized for each compound as described for a previous study (<xref rid="R17" ref-type="bibr">Ma et al. 2025</xref>).</p></sec><sec id="S13"><title>Immunoblotting</title><p id="P30">Lung tissues treated as indicated above were extracted in a lysis buffer (10 mM Tris, pH 7.4, 1% SDS) with a 1x proteinase inhibitor cocktail (Thermo Fisher Scientific) using a tissue homogenizer (Omni International, GA, USA) following sonication for 10 seconds. The supernatant was collected and combined for each treated group (3 samples/each treated group). Tissue proteins (20 &#x003bc;g each sample) were fractionated on a 8 or 10% SDS-PAGE gel and transferred onto a nitrocellulose membrane. The membrane was incubated with 5% nonfat dry milk in tris-buffered saline with 0.05% Tween 20 for 1 hour at room temperature to block nonspecific binding, before incubation with primary antibodies. The primary antibodies used were mouse anti-CD68 (1:200, Novus Biologicals, Centennial, CO, USA), mouse anti-CD206 (1:250, Abcam), or mouse anti-&#x003b2;-actin (1:4,000, Millipore Sigma) antibodies. After incubation with horseradish peroxidase-conjugated goat anti-mouse or goat anti-rabbit IgG (both from Jackson ImmunoResearch laboratories, West Grove, PA; 1:5,000), immunoreactive bands were developed with Enhanced chemiluminescence (Thermo Fisher Scientific) on X-ray films. Film images were scanned using HP scanjet (Hewlett-Packard, Palo Alto, CA, USA) and were used to quantify each band with ImageJ software (NIH) with normalization to &#x003b2;-actin level.</p></sec><sec id="S14"><title>Enzyme-linked immunosorbent assay (ELISA)</title><p id="P31">Proinflammatory type 1 (IL-1&#x003b2;, TNF-&#x003b1;) or type 2 cytokines (IL-4, IL-13) were detected in lung tissue extracts collected from mouse lungs exposed to DM or MWCNTs for the indicated dose and days using ELISA (three mice each group). All ELISA kits were purchased from MyBioSource (San Diego, CA, USA) and measurement was performed by following the manufacturer&#x02019;s protocol using a microplate reader equipped with the GEN5 software (Agilent).</p></sec><sec id="S15"><title>Statistical analysis</title><p id="P32">Statistical comparisons between two means were performed using Welch&#x02019;s t-test, which accounts for possible unequal variances. Comparisons of multiple means were perfomed using mixed-model one-way analyses of vairance (AVOVA), followed by posthoc comparisons between two means. For LC&#x02013;MS/MS analysis, means &#x000b1; SD obtained from the lungs of four animals in each group were calculated. For cell culture analysis, means &#x000b1; SD from four separate cell populations were used. Statistical analysis was conducted using the BioRender software (Science Suite Inc. DBA BioRender, Toronto, Ontario, Canada). Significance was set at <italic toggle="yes">p</italic> &#x0003c; 0.05 and indicated as follows: ns (non-significance), *<italic toggle="yes">p</italic> &#x0003c; 0.05; **<italic toggle="yes">p</italic> &#x0003c; 0.01; ***<italic toggle="yes">p</italic> &#x0003c; 0.001; and ****<italic toggle="yes">p</italic> &#x0003c; 0.0001.</p></sec></sec><sec id="S16"><title>Result</title><sec id="S17"><title>MWCNTs induced inflammation-to-resolution transition at 7 days post-exposure in mouse lung</title><p id="P33">The Mitsui-7 MWCNTs administered at a single dose induced acute inflammation in mouse lungs that exhibited time-dependent polarization and resolution. Acute inflammation was most prominent at 1-day post-exposure, characterized by polarization of macrophages into M1 cells (<xref rid="F1" ref-type="fig">Figure 1(B)</xref>) and production of high levels of proinflammatory cytokines TNF-&#x003b1; and IL-1&#x003b2; (<xref rid="F1" ref-type="fig">Figures 1(C</xref> and <xref rid="F1" ref-type="fig">D)</xref>), consistent with it being M1- and neutrophilic type 1 inflammation (<xref rid="R9" ref-type="bibr">Dong et al. 2015</xref>; <xref rid="R14" ref-type="bibr">Lim et al. 2020</xref>; <xref rid="R17" ref-type="bibr">Ma et al. 2025</xref>).</p><p id="P34">At 7-days post-exposure, lung inflammation was marked by polarization of macrophages into M2 cells (<xref rid="F1" ref-type="fig">Figure 1(B)</xref>) and production of high levels of pro-resolving cytokines IL-4 and IL-13 (<xref rid="F1" ref-type="fig">Figures 1(E</xref> and <xref rid="F1" ref-type="fig">F)</xref>). Lung lesions at 7-days post-exposure were further examined by immunohistochemistry. In vehicle-exposed lungs, the alveolar structure was well-preserved, with a low but detectable level of neutrophils present in both alveolar sacs and septa (<xref rid="F2" ref-type="fig">Figure 2(A)</xref>). MWCNTs significantly increased the cellularity in the lung, particularly in inflammatory foci where MWCNTs were visible as black deposits (<xref rid="F2" ref-type="fig">Figure 2(B)</xref>). MWCNT exposure resulted in a doubling of neutrophil numbers, although this increase did not reach statistical significance (<xref rid="F2" ref-type="fig">Figure 2(E)</xref>). In contrast, the number of macrophages in the alveolar sacs increased dramatically, with MWCNTs causing a 7.7-fold increase in macrophage numbers in both the alveolar sacs and interstitial space (<xref rid="F2" ref-type="fig">Figures 2(C</xref>, <xref rid="F2" ref-type="fig">D</xref> and <xref rid="F2" ref-type="fig">F)</xref>). Many macrophages formed clusters and contained engulfed MWCNT particles.</p><p id="P35">These results indicate a phenotypic switch from type 1 to type 2 inflammation at 7-days post-exposure. In view of the critical role of type 2 responses in inflammation resolution and tissue repair, we posited that MWCNTs activate the production of SPMs to promote the resolution of inflammation at 7 days post-exposure where a transition from acute inflammation to fibrotic progression was suggested (<xref rid="R6" ref-type="bibr">Dong and Ma 2018b</xref>; <xref rid="R16" ref-type="bibr">Ma 2020</xref>).</p></sec><sec id="S18"><title>MWCNTs stimulated phagocytosis and induced accumulation of phospholipids in macrophages in vitro</title><p id="P36">Given that a significant portion of macrophages in the lungs of MWCNT-exposed mice contained engulfed MWCNTs, we investigated the impact of MWCNT phagocytosis on the accumulation of phospholipids, which can serve as precursors for ILMs and SPMs in macrophages. J774A.1 murine macrophages were exposed to either vehicle control or MWCNTs at a concentration of 2 &#x003bc;g/mL for 24 hours. Following treatment, cells were stained with the LipidTox Red Phospholipidosis reagent (LTRP) to visualize intracellular phospholipids.</p><p id="P37">As shown in <xref rid="F3" ref-type="fig">Figure 3</xref>, vehicle-exposed cells exhibited low levels of LTRP fluorescence, indicating minimal phospholipid accumulation (<xref rid="F3" ref-type="fig">Figures 3(A</xref>-<xref rid="F3" ref-type="fig">C)</xref>). In contrast, MWCNT-treated cells displayed a substantial increase in LTRP fluorescence, which did not overlap with DAPI fluorescence, suggesting significant accumulation of phospholipids in the cytoplasm (<xref rid="F3" ref-type="fig">Figures 3(D</xref>-<xref rid="F3" ref-type="fig">F)</xref>). Quantitative analysis revealed increases in mean area per cell, mean intensity per cell, and mean intensity per DAPI-positive cell in MWCNT-exposed macrophages, all with statistical significance (<xref rid="F3" ref-type="fig">Figures 3(G</xref>-<xref rid="F3" ref-type="fig">I)</xref>). The DAPI fluorescence levels remained comparable between vehicle- and MWCNT-exposed cells (<xref rid="F3" ref-type="fig">Figures 3(J</xref>-<xref rid="F3" ref-type="fig">K)</xref>). These findings support the notion that MWCNTs stimulate the release of phospholipids from membranes in macrophages, potentially serving as precursors for the synthesis of lipid mediators.</p></sec><sec id="S19"><title>COX-dependent production of PGs and TXs from AA</title><p id="P38">To identify and quantify ILMs and SPMs, we performed targeted lipidomics analysis of 36 LMs using UPLC&#x02013;MS/MS. The analysis revealed that MWCNTs significantly elevated the levels of several inflammatory lipid mediators at 7-days post-exposure. As illustrated in <xref rid="F4" ref-type="fig">Figure 4(A)</xref>, the major pathways involved in the production of ILMs from arachidonic acid via COX-dependent synthesis were activated. At this time point, AA levels were detected in both vehicle- and MWCNT-exposed lungs without a significant difference (<xref rid="F4" ref-type="fig">Figure 4(B)</xref>). However, the levels of three major prostaglandins&#x02014;PGH2, PGE2, and PGD2&#x02014;were significantly increased in MWCNT-exposed lungs compared to vehicle controls (<xref rid="F4" ref-type="fig">Figures 4(C</xref>-<xref rid="F4" ref-type="fig">E)</xref>). Additionally, thromboxane B2 (TXB2), a major TX, was also significantly elevated by MWCNT exposure (<xref rid="F4" ref-type="fig">Figure 4(F)</xref>). Prostaglandin F2&#x003b1; (PGF2&#x003b1;) was detected in vehicle-treated lungs and showed an increase in MWCNT-exposed lungs, although this increase did not reach statistical significance (<xref rid="F4" ref-type="fig">Figure 4(G)</xref>).</p></sec><sec id="S20"><title>ALOX-dependent production of LTs and LXs from AA</title><p id="P39">The analysis of leukotrienes and lipoxins produced from arachidonic acid via the Alox-mediated pathway revealed significant findings. As shown in <xref rid="F5" ref-type="fig">Figure 5(A)</xref>, LTs and LXs are formed from AA via separate Alox pathways. MWCNTs significantly elevated the levels of LTB4, a major chemoattractant for leukocytes, compared to control, indicating its critical role in the recruitment of polymorphonuclear leukocytes during inflammation (<xref rid="F5" ref-type="fig">Figure 5(B)</xref>). Additionally, 5-HETE, which is produced from the same precursor as LTB4, was detected in vehicle-exposed lungs and showed an increase in MWCNT-exposed lungs, although this increase did not reach a statistical significance (<xref rid="F5" ref-type="fig">Figure 5(C)</xref>).</p><p id="P40">Conversely, LXB4, a major SPM that inhibits leukocyte recruitment, is produced via Alox15. LXB4 was detected at high levels in vehicle-exposed lungs and was significantly elevated by MWCNT exposure, showing a 9.3-fold increase (<xref rid="F5" ref-type="fig">Figure 5(D)</xref>). Furthermore, 15-HETE, produced from the same precursor as LXB4, was also significantly elevated by MWCNTs (<xref rid="F5" ref-type="fig">Figure 5(E)</xref>). In contrast, 12-HETE was detected in both vehicle- and MWCNT-exposed lungs, but the means did not differ significantly (<xref rid="F5" ref-type="fig">Figure 5(F)</xref>).</p></sec><sec id="S21"><title>Induced production of SPMs from DHA</title><p id="P41">The lipidomics analysis also assessed the production of SPMs from docosahexaenoic acid. The pathways and major metabolites of SPMs from DHA were shown in <xref rid="F6" ref-type="fig">Figure 6(A)</xref>. DHA levels were detected at high levels in mouse lungs, with MWCNT exposure leading to an increase that did not reach statistical significance (<xref rid="F6" ref-type="fig">Figure 6(B)</xref>). Notably, three resolvins (RvD2, RvD3, and RvD5) were found at picogram levels (<xref rid="F6" ref-type="fig">Figures 6(C</xref>-<xref rid="F6" ref-type="fig">E)</xref>), with RvD5 showing a statistically significant increase in MWCNT-exposed lungs compared to controls. Additionally, protectin D1 (PD1), protectin DX (PDX), and 17-hydroxydocosahexaenoic acid (HDHA), all produced from the same precursor as the RvDs, were elevated by MWCNTs, with the increases for PDX and 17-HDHA reaching statistical significance (<xref rid="F6" ref-type="fig">Figures 6(F</xref>-<xref rid="F6" ref-type="fig">H)</xref>). Maresins (MaRs), including MaR1 and 14S-HDHA, which are produced from 14S-hydroperoxydocosahexaenoic acid (HPDHA) via the Alox12-dependent pathway, were also significantly increased by MWCNT exposure (<xref rid="F6" ref-type="fig">Figures 6(I</xref> and <xref rid="F6" ref-type="fig">J)</xref>).</p></sec><sec id="S22"><title>Induced production of SPMs from EPA</title><p id="P42">The pathways and enzymes involved in the production of resolvin Es and lipoxins from eicosapentaenoic acid were examined (<xref rid="F7" ref-type="fig">Figure 7(A)</xref>). EPA levels were detected at high levels in vehicle-exposed lungs, with MWCNT exposure leading to an increase that did not reach statistical significance (<xref rid="F7" ref-type="fig">Figure 7(B)</xref>). However, both RvE2 and 18-hydroxyeicosapentaenoic acid (HEPE) were significantly increased by MWCNTs (<xref rid="F7" ref-type="fig">Figures 7(C</xref> and <xref rid="F7" ref-type="fig">D)</xref>). Additionally, RvE4 and 15-HEPE, produced by Alox15 and Alox5, were detected and showed increases in MWCNT-exposed lungs, with the increase for 15-HEPE reaching a statistical significance (<xref rid="F7" ref-type="fig">Figures 7(E</xref> and <xref rid="F7" ref-type="fig">F)</xref>). Lastly, both 5-HEPE and 12-HEPE were detected and increased by MWCNTs, although these increases did not reach a statistical significance (<xref rid="F7" ref-type="fig">Figures 7(G</xref> and <xref rid="F7" ref-type="fig">H)</xref>).</p></sec></sec><sec id="S23"><title>Discussion</title><p id="P43">In this study, we demonstrated that pulmonary exposure to fibrogenic multiwalled carbon nanotubes stimulates the synthesis of both inflammatory lipid mediators and specialized pro-resolving mediators in mouse lungs at 7-days post-exposure. Our findings highlight the complex interplay between inflammation and resolution mechanisms in response to inhaled nanoparticles, providing insights into the temporal dynamics of lipid mediator production during the transition from acute inflammation to resolution.</p><p id="P44">The acute inflammatory response observed at 1-day post-exposure to MWCNTs is characterized by significant neutrophil infiltration and the activation of proinflammatory pathways, including the rapid synthesis of ILMs such as prostaglandins and leukotrienes. This initial phase is critical for the clearance of inhaled particles; however, it can also lead to tissue damage if not resolved in a timely manner (<xref rid="R4" ref-type="bibr">Dong and Ma 2015</xref>). The subsequent transition to a macrophage-predominant response at 7-days post-exposure indicates a shift toward resolution, where M2 macrophages play a pivotal role in mediating tissue repair and the clearance of apoptotic cells and debris (<xref rid="R16" ref-type="bibr">Ma 2020</xref>).</p><p id="P45">Our lipidomics analysis revealed that MWCNTs significantly increased the production of both ILMs and SPMs at 7-days post-exposure. Among the LMs elevated, PGE2, PGD2, and LTB4 derived from arachidonic acid are potent ILMs that play critical roles in the initiation and amplification of acute inflammation. These ILMs promote inflammatory vascular and broncho responses and the chemotaxis and activation of various leukocytes, particularly, neutrophils and M1 macrophages, at or near the site of inflammation. Elevation of TXB2 signifies increased aggregation and activation of platelets that further increase inflammatory blood and vascular responses in acute inflammation. On the other hand, LXB4, derived from AA; RvD5, PDX, and MaR1 derived from DHA; and RvE2 derived from EPA, are potent SPMs elevated in mouse lungs by MWCNTs. Among the SPMs, LXB4 potently inhibits leukocyte recruitment to dampen and resolve inflammation, whereas the resolvins boost resolution responses by promoting type 2 inflammation while inhibiting type 1 inflammation through regulating the polarization of immune cells (<xref rid="R26" ref-type="bibr">Serhan, Chiang, and Dalli 2015</xref>).</p><p id="P46">Therefore, MWCNTs stimulate the production of a signature of ILMs and SPMs to provoke an inflammatory response that continues the clearance of deposited nanoparticles and, at the same time, initiates mechanisms aimed at resolving inflammation to limit tissue damage, promote tissue repair, and maintain pulmonary homeostasis. The observed accumulation of phospholipids in macrophages following MWCNT exposure further supports the notion that macrophages are actively engaged in lipid mediator biosynthesis. Phospholipids can serve as precursors for the synthesis of both ILMs and SPMs, and their increased levels in macrophages may reflect enhanced membrane remodeling and the activation of lipid metabolic pathways. This finding aligns with previous studies indicating that macrophages can modulate their lipid profiles in response to environmental stimuli, thereby influencing the local inflammatory milieu (<xref rid="R14" ref-type="bibr">Lim et al. 2020</xref>, <xref rid="R16" ref-type="bibr">Ma 2020</xref>, <xref rid="R17" ref-type="bibr">Ma et al. 2025</xref>).</p><p id="P47">The biphasic nature of the inflammatory response to MWCNTs, characterized by an initial neutrophilic phase followed by an M2 macrophage-dominated phase, mirrors the dynamics observed in other models of inflammation in the lung and other organs (<xref rid="R31" ref-type="bibr">Wynn and Ramalingam 2012</xref>). This biphasic response is essential for effective resolution, as it allows for the timely clearance of inflammatory cells and the restoration of tissue homeostasis. The transition from type 1 to type 2 inflammation, as evidenced by the shift from neutrophil to macrophage predominance, is a critical determinant of whether the inflammatory response resolves appropriately or progresses to chronic inflammation and fibrosis (<xref rid="R27" ref-type="bibr">Serhan, Chiang, and Van Dyke 2008</xref>). If and how lipid mediators directly impact fibrotic progression remain unclear and warrant further investigation.</p><p id="P48">The findings of this study have significant implications for understanding the health risks associated with exposure to nanomaterials and other respirable particles. Given the potential for MWCNTs to induce both acute and chronic inflammatory responses, it is crucial to further investigate the mechanisms underlying these effects and their long-term consequences on lung health. Future studies should explore the signaling pathways involved in the production of ILMs and SPMs in response to MWCNTs, as well as the potential for therapeutic interventions targeting these pathways to mitigate the adverse effects of nanomaterial exposure.</p><p id="P49">In conclusion, our study provides new insights into the role of lipid mediators in the inflammatory response to MWCNTs, highlighting the importance of both ILMs and SPMs in the transition from inflammation to resolution. Understanding these mechanisms may inform the development of strategies to prevent or treat lung diseases associated with exposure to inhaled nanoparticles.</p></sec></body><back><ack id="S25"><title>Acknowledgement</title><p id="P51">The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.</p><p id="P52">Mention of any company or product does not constitute endorsement by the National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.</p><sec id="S26"><title>Funding</title><p id="P53">This work was funded by the Nanotechnology Research Center program under Grant 9390P0G (Q.M.) at the National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, USA.</p></sec></ack><fn-group><fn fn-type="COI-statement" id="FN2"><p id="P54">Disclosure statement</p><p id="P55">No potential conflict of interest was reported by the authors.</p></fn></fn-group><sec sec-type="data-availability" id="S24"><title>Data availability statement</title><p id="P50">The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.</p></sec><ref-list><title>References</title><ref id="R1"><mixed-citation publication-type="journal"><name><surname>Chiang</surname><given-names>N</given-names></name>, and <name><surname>Serhan</surname><given-names>CN</given-names></name>. <year>2020</year>. &#x0201c;<article-title>Specialized Pro-Resolving Mediator Network: An Update on Production and Actions</article-title>.&#x0201d; <source>Essays in Biochemistry</source>
<volume>64</volume> (<issue>3</issue>): <fpage>443</fpage>&#x02013;<lpage>462</lpage>. <pub-id pub-id-type="doi">10.1042/EBC20200018</pub-id>.<pub-id pub-id-type="pmid">32885825</pub-id>
</mixed-citation></ref><ref id="R2"><mixed-citation publication-type="journal"><name><surname>De Volder</surname><given-names>MF</given-names></name>, <name><surname>Tawfick</surname><given-names>SH</given-names></name>, <name><surname>Baughman</surname><given-names>RH</given-names></name>, and <name><surname>Hart</surname><given-names>AJ</given-names></name>. <year>2013</year>. &#x0201c;<article-title>Carbon Nanotubes: present and Future Commercial Applications</article-title>.&#x0201d; <source>Science (New York, N.Y.)</source>
<volume>339</volume> (<issue>6119</issue>): <fpage>535</fpage>&#x02013;<lpage>539</lpage>. <pub-id pub-id-type="doi">10.1126/science.1222453</pub-id>.<pub-id pub-id-type="pmid">23372006</pub-id>
</mixed-citation></ref><ref id="R3"><mixed-citation publication-type="journal"><name><surname>Donaldson</surname><given-names>K</given-names></name>, <name><surname>Aitken</surname><given-names>R</given-names></name>, <name><surname>Tran</surname><given-names>L</given-names></name>, <name><surname>Stone</surname><given-names>V</given-names></name>, <name><surname>Duffin</surname><given-names>R</given-names></name>, <name><surname>Forrest</surname><given-names>G</given-names></name>, and <name><surname>Alexander</surname><given-names>A</given-names></name>. <year>2006</year>. &#x0201c;<article-title>Carbon Nanotubes: A Review of Their Properties in Relation to Pulmonary Toxicology and Workplace Safety</article-title>.&#x0201d; <source>Toxicological Sciences: An Official Journal of the Society of Toxicology</source>
<volume>92</volume> (<issue>1</issue>): <fpage>5</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfj130</pub-id>.<pub-id pub-id-type="pmid">16484287</pub-id>
</mixed-citation></ref><ref id="R4"><mixed-citation publication-type="journal"><name><surname>Dong</surname><given-names>J</given-names></name>, and <name><surname>Ma</surname><given-names>Q</given-names></name>. <year>2015</year>. &#x0201c;<article-title>Advances in Mechanisms and Signaling Pathways of Carbon Nanotube Toxicity</article-title>.&#x0201d; <source>Nanotoxicology</source>
<volume>9</volume> (<issue>5</issue>): <fpage>658</fpage>&#x02013;<lpage>676</lpage>. <pub-id pub-id-type="doi">10.3109/174</pub-id>35390.2015.1009187.<pub-id pub-id-type="pmid">25676622</pub-id>
</mixed-citation></ref><ref id="R5"><mixed-citation publication-type="journal"><name><surname>Dong</surname><given-names>J</given-names></name>, and <name><surname>Ma</surname><given-names>Q</given-names></name>. <year>2016</year>. &#x0201c;<article-title>In Vivo Activation of a T Helper 2-Driven Innate Immune Response in Lung Fibrosis Induced by Multi-Walled Carbon Nanotubes</article-title>.&#x0201d; <source>Archives of Toxicology</source>
<volume>90</volume> (<issue>9</issue>): <fpage>2231</fpage>&#x02013;<lpage>2248</lpage>. <pub-id pub-id-type="doi">10.1007/s00204-016-1711-1</pub-id>.<pub-id pub-id-type="pmid">27106021</pub-id>
</mixed-citation></ref><ref id="R6"><mixed-citation publication-type="journal"><name><surname>Dong</surname><given-names>J</given-names></name>, and <name><surname>Ma</surname><given-names>Q</given-names></name>. <year>2018b</year>. &#x0201c;<article-title>Macrophage Polarization and Activation at the Interface of Multi-Walled Carbon Nanotube-Induced Pulmonary Inflammation and Fibrosis</article-title>.&#x0201d; <source>Nanotoxicology</source>
<volume>12</volume> (<issue>2</issue>): <fpage>153</fpage>&#x02013;<lpage>168</lpage>. <pub-id pub-id-type="doi">10.1080/17</pub-id>435390.2018.1425501.<pub-id pub-id-type="pmid">29338488</pub-id>
</mixed-citation></ref><ref id="R7"><mixed-citation publication-type="journal"><name><surname>Dong</surname><given-names>J</given-names></name>, and <name><surname>Ma</surname><given-names>Q</given-names></name>. <year>2018a</year>. &#x0201c;<article-title>Type 2 Immune Mechanisms in Carbon Nanotube-Induced Lung Fibrosis</article-title>.&#x0201d; <source>Frontiers in Immunology</source>
<volume>9</volume>: <fpage>1120</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.01120</pub-id>.<pub-id pub-id-type="pmid">29872441</pub-id>
</mixed-citation></ref><ref id="R8"><mixed-citation publication-type="journal"><name><surname>Dong</surname><given-names>J</given-names></name>, and <name><surname>Ma</surname><given-names>Q</given-names></name>. <year>2019</year>. &#x0201c;<article-title>Integration of Inflammation, Fibrosis, and Cancer Induced by Carbon Nanotubes</article-title>.&#x0201d; <source>Nanotoxicology</source>
<volume>13</volume> (<issue>9</issue>): <fpage>1244</fpage>&#x02013;<lpage>1274</lpage>. <pub-id pub-id-type="doi">10.1080/17435390.2019.1651920</pub-id>.<pub-id pub-id-type="pmid">31537143</pub-id>
</mixed-citation></ref><ref id="R9"><mixed-citation publication-type="journal"><name><surname>Dong</surname><given-names>J</given-names></name>, <name><surname>Porter</surname><given-names>DW</given-names></name>, <name><surname>Batteli</surname><given-names>LA</given-names></name>, <name><surname>Wolfarth</surname><given-names>MG</given-names></name>, <name><surname>Richardson</surname><given-names>DL</given-names></name>, and <name><surname>Ma</surname><given-names>Q</given-names></name>. <year>2015</year>. &#x0201c;<article-title>Pathologic and Molecular Profiling of Rapid-Onset Fibrosis and Inflammation Induced by Multi-Walled Carbon Nanotubes</article-title>.&#x0201d; <source>Archives of Toxicology</source>
<volume>89</volume> (<issue>4</issue>): <fpage>621</fpage>&#x02013;<lpage>633</lpage>. <pub-id pub-id-type="doi">10.1007/s00204-014-1428-y</pub-id>.<pub-id pub-id-type="pmid">25510677</pub-id>
</mixed-citation></ref><ref id="R10"><mixed-citation publication-type="journal"><name><surname>Erdely</surname><given-names>A</given-names></name>, <name><surname>Dahm</surname><given-names>M</given-names></name>, <name><surname>Chen</surname><given-names>BT</given-names></name>, <name><surname>Zeidler-Erdely</surname><given-names>PC</given-names></name>, <name><surname>Fernback</surname><given-names>JE</given-names></name>, <name><surname>Birch</surname><given-names>ME</given-names></name>, <name><surname>Evans</surname><given-names>DE</given-names></name>, <etal/>
<year>2013</year>. &#x0201c;<article-title>Carbon Nanotube Dosimetry: From Workplace Exposure Assessment to Inhalation Toxicology</article-title>.&#x0201d; <source>Particle and Fibre Toxicology</source>
<volume>10</volume> (<issue>1</issue>): <fpage>53</fpage>. <pub-id pub-id-type="doi">10.1186/1743-8977-10-53</pub-id>.<pub-id pub-id-type="pmid">24144386</pub-id>
</mixed-citation></ref><ref id="R11"><mixed-citation publication-type="journal"><name><surname>Galer</surname><given-names>DM</given-names></name>, <name><surname>Leung</surname><given-names>HW</given-names></name>, <name><surname>Sussman</surname><given-names>RG</given-names></name>, and <name><surname>Trzos</surname><given-names>RJ</given-names></name>. <year>1992</year>. &#x0201c;<article-title>Scientific and Practical Considerations for the Development of Occupational Exposure Limits (OELs) for Chemical Substances</article-title>.&#x0201d; <source>Regulatory Toxicology and Pharmacology: RTP</source>
<volume>15</volume> (<issue>3</issue>): <fpage>291</fpage>&#x02013;<lpage>306</lpage>. <pub-id pub-id-type="doi">10.1016/0273-2300</pub-id>(92)90040-g.<pub-id pub-id-type="pmid">1509122</pub-id>
</mixed-citation></ref><ref id="R12"><mixed-citation publication-type="journal"><name><surname>Hughes</surname><given-names>KJ</given-names></name>, <name><surname>Cheng</surname><given-names>J</given-names></name>, <name><surname>Iyer</surname><given-names>KA</given-names></name>, <name><surname>Ralhan</surname><given-names>K</given-names></name>, <name><surname>Ganesan</surname><given-names>M</given-names></name>, <name><surname>Hsu</surname><given-names>CW</given-names></name>, <name><surname>Zhan</surname><given-names>Y</given-names></name>, <etal/>
<year>2024</year>. &#x0201c;<article-title>Unveiling Trends: Nanoscale Materials Shaping Emerging Biomedical Applications</article-title>.&#x0201d; <source>ACS Nano</source>
<volume>18</volume> (<issue>26</issue>): <fpage>16325</fpage>&#x02013;<lpage>16342</lpage>. <pub-id pub-id-type="doi">10.1021/acsna-no.4c04514</pub-id>.<pub-id pub-id-type="pmid">38888229</pub-id>
</mixed-citation></ref><ref id="R13"><mixed-citation publication-type="journal"><name><surname>Lim</surname><given-names>CS</given-names></name>, <name><surname>Veltri</surname><given-names>B</given-names></name>, <name><surname>Kashon</surname><given-names>M</given-names></name>, <name><surname>Porter</surname><given-names>DW</given-names></name>, and <name><surname>Ma</surname><given-names>Q</given-names></name>. <year>2023</year>. &#x0201c;<article-title>Multi-Walled Carbon Nanotubes Induce Arachidonate 5-Lipoxygenase Expression and Enhance the Polarization and Function of M1 Macrophages In Vitro</article-title>.&#x0201d; <source>Nanotoxicology</source>
<volume>17</volume> (<issue>3</issue>): <fpage>249</fpage>&#x02013;<lpage>269</lpage>. <pub-id pub-id-type="doi">10.1080/17435390.2023.2204161</pub-id>.<pub-id pub-id-type="pmid">37115655</pub-id>
</mixed-citation></ref><ref id="R14"><mixed-citation publication-type="journal"><name><surname>Lim</surname><given-names>CS</given-names></name>, <name><surname>Porter</surname><given-names>DW</given-names></name>, <name><surname>Orandle</surname><given-names>MS</given-names></name>, <name><surname>Green</surname><given-names>BJ</given-names></name>, <name><surname>Barnes</surname><given-names>MA</given-names></name>, <name><surname>Croston</surname><given-names>TL</given-names></name>, <name><surname>Wolfarth</surname><given-names>MG</given-names></name>, <etal/>
<year>2020</year>. &#x0201c;<article-title>Resolution of Pulmonary Inflammation Induced by Carbon Nanotubes and Fullerenes in Mice: Role of Macrophage Polarization</article-title>.&#x0201d; <source>Frontiers in Immunology</source>
<volume>11</volume>: <fpage>1186</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2020.01186</pub-id>.<pub-id pub-id-type="pmid">32595644</pub-id>
</mixed-citation></ref><ref id="R15"><mixed-citation publication-type="journal"><name><surname>Lim</surname><given-names>CS</given-names></name>, <name><surname>Gu</surname><given-names>JK</given-names></name>, and <name><surname>Ma</surname><given-names>Q</given-names></name>. <year>2025</year>. &#x0201c;<article-title>The ETS Domain-Containing Hematopoietic Transcription Factor PU.1 Mediates the Induction of Arachidonate 5-Lipoxygenase by Multi-Walled Carbon Nanotubes in Macrophages In Vitro</article-title>.&#x0201d; <source>Archives of Toxicology</source>
<volume>99</volume> (<issue>2</issue>): <fpage>597</fpage>&#x02013;<lpage>610</lpage>. <pub-id pub-id-type="doi">10.1007/s00204-024-03925-w</pub-id>.<pub-id pub-id-type="pmid">39688681</pub-id>
</mixed-citation></ref><ref id="R16"><mixed-citation publication-type="journal"><name><surname>Ma</surname><given-names>Q</given-names></name>. <year>2020</year>. &#x0201c;<article-title>Polarization of Immune Cells in the Pathologic Response to Inhaled Particulates</article-title>.&#x0201d; <source>Frontiers in Immunology</source>
<volume>11</volume>: <fpage>1060</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2020.01060</pub-id>.<pub-id pub-id-type="pmid">32625201</pub-id>
</mixed-citation></ref><ref id="R17"><mixed-citation publication-type="journal"><name><surname>Ma</surname><given-names>Q</given-names></name>, <name><surname>LeBouf</surname><given-names>RF</given-names></name>, <name><surname>Rimayi</surname><given-names>C</given-names></name>, <name><surname>Lim</surname><given-names>CS</given-names></name>, <name><surname>Fekedulegn</surname><given-names>D</given-names></name>, <name><surname>Park</surname><given-names>JH</given-names></name>, and <name><surname>Porter</surname><given-names>DW</given-names></name>. <year>2025</year>. &#x0201c;<article-title>Sterile inflammation in mouse lung driven by lipid mediator pathways following MWCNT exposure</article-title>.&#x0201d; <source>Chemical Research in Toxicology, Articles ASAP</source>, Publication Date (Web): <month>December</month>
<day>15</day>, 2025. <pub-id pub-id-type="doi">10.1021/acs.chemrestox.5c00470</pub-id>.</mixed-citation></ref><ref id="R18"><mixed-citation publication-type="journal"><name><surname>Mercer</surname><given-names>RR</given-names></name>, <name><surname>Scabilloni</surname><given-names>JF</given-names></name>, <name><surname>Hubbs</surname><given-names>AF</given-names></name>, <name><surname>Battelli</surname><given-names>LA</given-names></name>, <name><surname>McKinney</surname><given-names>W</given-names></name>, <name><surname>Friend</surname><given-names>S</given-names></name>, <name><surname>Wolfarth</surname><given-names>MG</given-names></name>, <name><surname>Andrew</surname><given-names>M</given-names></name>, <name><surname>Castranova</surname><given-names>V</given-names></name>, and <name><surname>Porter</surname><given-names>DW</given-names></name>. <year>2013</year>. &#x0201c;<article-title>Distribution and Fibrotic Response following Inhalation Exposure to Multi-Walled Carbon Nanotubes</article-title>.&#x0201d; <source>Particle and Fibre Toxicology</source>
<volume>10</volume> (<issue>1</issue>): <fpage>33</fpage>. <pub-id pub-id-type="doi">10.1186/1743-8977-10-33</pub-id>.<pub-id pub-id-type="pmid">23895460</pub-id>
</mixed-citation></ref><ref id="R19"><mixed-citation publication-type="book"><collab>NIOSH</collab>. <year>2013</year>. <source>Occupational exposure to carbon nanotubes and nanofibers</source>. <publisher-loc>Cincinnati, OH</publisher-loc>: <publisher-name>U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH)</publisher-name>. Publication No. 2013-145. <ext-link xlink:href="https://www.cdc.gov/niosh/docs/2013-145" ext-link-type="uri">https://www.cdc.gov/niosh/docs/2013-145</ext-link>.&#x0201d;</mixed-citation></ref><ref id="R20"><mixed-citation publication-type="book"><name><surname>Phalen</surname><given-names>RF</given-names></name>
<year>2008</year>. <part-title>The Respiratory Tract</part-title>. <source>Inhalation Studies: Foundations and Techniques</source>. <name><surname>Phalen</surname><given-names>RF</given-names></name>. <publisher-loc>Boca Raton</publisher-loc>, <publisher-name>CRC Press</publisher-name>, <fpage>33</fpage>&#x02013;<lpage>68</lpage>.</mixed-citation></ref><ref id="R21"><mixed-citation publication-type="journal"><name><surname>Porter</surname><given-names>DW</given-names></name>, <name><surname>Hubbs</surname><given-names>AF</given-names></name>, <name><surname>Mercer</surname><given-names>RR</given-names></name>, <name><surname>Wu</surname><given-names>N</given-names></name>, <name><surname>Wolfarth</surname><given-names>MG</given-names></name>, <name><surname>Sriram</surname><given-names>K</given-names></name>, <name><surname>Leonard</surname><given-names>S</given-names></name>, <etal/>
<year>2010</year>. &#x0201c;<article-title>Mouse Pulmonary Dose- and Time Course-Responses Induced by Exposure to Multi-Walled Carbon Nanotubes</article-title>.&#x0201d; <source>Toxicology</source>
<volume>269</volume> (<issue>2&#x02013;3</issue>): <fpage>136</fpage>&#x02013;<lpage>147</lpage>. <pub-id pub-id-type="doi">10.1016/j.tox.2009.10.017</pub-id>.<pub-id pub-id-type="pmid">19857541</pub-id>
</mixed-citation></ref><ref id="R22"><mixed-citation publication-type="journal"><name><surname>Rao</surname><given-names>GV</given-names></name>, <name><surname>Tinkle</surname><given-names>S</given-names></name>, <name><surname>Weissman</surname><given-names>DN</given-names></name>, <name><surname>Antonini</surname><given-names>JM</given-names></name>, <name><surname>Kashon</surname><given-names>ML</given-names></name>, <name><surname>Salmen</surname><given-names>R</given-names></name>, <name><surname>Battelli</surname><given-names>LA</given-names></name>, <name><surname>Willard</surname><given-names>PA</given-names></name>, <name><surname>Hoover</surname><given-names>MD</given-names></name>, and <name><surname>Hubbs</surname><given-names>AF</given-names></name>. <year>2003</year>. &#x0201c;<article-title>Efficacy of a Technique for Exposing the Mouse Lung to Particles Aspirated from the Pharynx</article-title>.&#x0201d; <source>Journal of Toxicology and Environmental Health. Part A</source>
<volume>66</volume> (<issue>15</issue>): <fpage>1441</fpage>&#x02013;<lpage>1452</lpage>. <pub-id pub-id-type="doi">10.1080/15287390306417</pub-id>.<pub-id pub-id-type="pmid">12857634</pub-id>
</mixed-citation></ref><ref id="R23"><mixed-citation publication-type="journal"><name><surname>Ricciotti</surname><given-names>E</given-names></name>, and <name><surname>FitzGerald</surname><given-names>GA</given-names></name>. <year>2011</year>. &#x0201c;<article-title>Prostaglandins and Inflammation</article-title>.&#x0201d; <source>Arteriosclerosis, Thrombosis, and Vascular Biology</source>
<volume>31</volume> (<issue>5</issue>): <fpage>986</fpage>&#x02013;<lpage>1000</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.110.207449</pub-id>.<pub-id pub-id-type="pmid">21508345</pub-id>
</mixed-citation></ref><ref id="R24"><mixed-citation publication-type="journal"><name><surname>Sayers</surname><given-names>BC</given-names></name>, <name><surname>Taylor</surname><given-names>AJ</given-names></name>, <name><surname>Glista-Baker</surname><given-names>EE</given-names></name>, <name><surname>Shipley-Phillips</surname><given-names>JK</given-names></name>, <name><surname>Dackor</surname><given-names>RT</given-names></name>, <name><surname>Edin</surname><given-names>ML</given-names></name>, <name><surname>Lih</surname><given-names>FB</given-names></name>, <etal/>
<year>2013</year>. &#x0201c;<article-title>Role of Cyclooxygenase-2 in Exacerbation of Allergen-Induced Airway Remodeling by Multiwalled Carbon Nanotubes</article-title>.&#x0201d; <source>American Journal of Respiratory Cell and Molecular Biology</source>
<volume>49</volume> (<issue>4</issue>): <fpage>525</fpage>&#x02013;<lpage>535</lpage>. <pub-id pub-id-type="doi">10.1165/rcmb.2013-0019OC</pub-id>.<pub-id pub-id-type="pmid">23642096</pub-id>
</mixed-citation></ref><ref id="R25"><mixed-citation publication-type="journal"><name><surname>Serhan</surname><given-names>CN</given-names></name>, and <name><surname>Savill</surname><given-names>J</given-names></name>. <year>2005</year>. &#x0201c;<article-title>Resolution of Inflammation: The Beginning Programs the End</article-title>.&#x0201d; <source>Nature Immunology</source>
<volume>6</volume> (<issue>12</issue>): <fpage>1191</fpage>&#x02013;<lpage>1197</lpage>. <pub-id pub-id-type="doi">10.1038/ni1276</pub-id>.<pub-id pub-id-type="pmid">16369558</pub-id>
</mixed-citation></ref><ref id="R26"><mixed-citation publication-type="journal"><name><surname>Serhan</surname><given-names>CN</given-names></name>, <name><surname>Chiang</surname><given-names>N</given-names></name>, and <name><surname>Dalli</surname><given-names>J</given-names></name>. <year>2015</year>. &#x0201c;<article-title>The Resolution Code of Acute Inflammation: Novel Pro-Resolving Lipid Mediators in Resolution</article-title>.&#x0201d; <source>Seminars in Immunology</source>
<volume>27</volume> (<issue>3</issue>): <fpage>200</fpage>&#x02013;<lpage>215</lpage>. <pub-id pub-id-type="doi">10.1016/j.smim.2015.03.004</pub-id>.<pub-id pub-id-type="pmid">25857211</pub-id>
</mixed-citation></ref><ref id="R27"><mixed-citation publication-type="journal"><name><surname>Serhan</surname><given-names>CN</given-names></name>, <name><surname>Chiang</surname><given-names>N</given-names></name>, and <name><surname>Van Dyke</surname><given-names>TE</given-names></name>. <year>2008</year>. &#x0201c;<article-title>Resolving Inflammation: dual anti-Inflammatory and Pro-Resolution Lipid Mediators</article-title>.&#x0201d; <source>Nature Reviews. Immunology</source>
<volume>8</volume> (<issue>5</issue>): <fpage>349</fpage>&#x02013;<lpage>361</lpage>. <pub-id pub-id-type="doi">10.1038/nri2294</pub-id>.</mixed-citation></ref><ref id="R28"><mixed-citation publication-type="journal"><name><surname>Sinnott</surname><given-names>SB</given-names></name>, and <name><surname>Andrews</surname><given-names>R</given-names></name>. <year>2001</year>. &#x0201c;<article-title>Carbon Nanotubes: Synthesis, Properties, and Applications</article-title>.&#x0201d; <source>Critical Reviews in Solid State and Materials Sciences</source>
<volume>26</volume> (<issue>3</issue>): <fpage>145</fpage>&#x02013;<lpage>249</lpage>. <pub-id pub-id-type="doi">10.1080/20014091104189</pub-id>.</mixed-citation></ref><ref id="R29"><mixed-citation publication-type="journal"><name><surname>Stone</surname><given-names>KC</given-names></name>, <name><surname>Mercer</surname><given-names>RR</given-names></name>, <name><surname>Gehr</surname><given-names>P</given-names></name>, <name><surname>Stockstill</surname><given-names>B</given-names></name>, and <name><surname>Crapo</surname><given-names>JD</given-names></name>. <year>1992</year>. &#x0201c;<article-title>Allometric Relationships of Cell Numbers and Size in the Mammalian Lung</article-title>.&#x0201d; <source>American Journal of Respiratory Cell and Molecular Biology</source>
<volume>6</volume> (<issue>2</issue>): <fpage>235</fpage>&#x02013;<lpage>243</lpage>. <pub-id pub-id-type="doi">10.1165/ajrcmb/6.2.235</pub-id>.<pub-id pub-id-type="pmid">1540387</pub-id>
</mixed-citation></ref><ref id="R30"><mixed-citation publication-type="journal"><name><surname>Suzui</surname><given-names>M</given-names></name>, <name><surname>Futakuchi</surname><given-names>M</given-names></name>, <name><surname>Fukamachi</surname><given-names>K</given-names></name>, <name><surname>Numano</surname><given-names>T</given-names></name>, <name><surname>Abdelgied</surname><given-names>M</given-names></name>, <name><surname>Takahashi</surname><given-names>S</given-names></name>, <name><surname>Ohnishi</surname><given-names>M</given-names></name>, <etal/>
<year>2016</year>. &#x0201c;<article-title>Multiwalled Carbon Nanotubes Intratracheally Instilled into the Rat Lung Induce Development of Pleural Malignant Mesothelioma and Lung Tumors</article-title>.&#x0201d; <source>Cancer Science</source>
<volume>107</volume> (<issue>7</issue>): <fpage>924</fpage>&#x02013;<lpage>935</lpage>. <pub-id pub-id-type="doi">10.1111/cas.12954</pub-id>.<pub-id pub-id-type="pmid">27098557</pub-id>
</mixed-citation></ref><ref id="R31"><mixed-citation publication-type="journal"><name><surname>Wynn</surname><given-names>TA</given-names></name>, and <name><surname>Ramalingam</surname><given-names>TR</given-names></name>. <year>2012</year>. &#x0201c;<article-title>Mechanisms of Fibrosis: Therapeutic Translation for Fibrotic Disease</article-title>.&#x0201d; <source>Nature Medicine</source>
<volume>18</volume> (<issue>7</issue>): <fpage>1028</fpage>&#x02013;<lpage>1040</lpage>. <pub-id pub-id-type="doi">10.1038/nm.2807</pub-id>.</mixed-citation></ref><ref id="R32"><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Q</given-names></name>, <name><surname>Huang</surname><given-names>JQ</given-names></name>, <name><surname>Qian</surname><given-names>WZ</given-names></name>, <name><surname>Zhang</surname><given-names>YY</given-names></name>, and <name><surname>Wei</surname><given-names>F</given-names></name>. <year>2013</year>. &#x0201c;<article-title>The Road for Nanomaterials Industry: A Review of Carbon Nanotube Production, Post-Treatment, and Bulk Applications for Composites and Energy Storage</article-title>.&#x0201d; <source>Small (Weinheim an Der Bergstrasse, Germany)</source>
<volume>9</volume> (<issue>8</issue>): <fpage>1237</fpage>&#x02013;<lpage>1265</lpage>. <pub-id pub-id-type="doi">10.1002/smll.201203252</pub-id>.<pub-id pub-id-type="pmid">23580370</pub-id>
</mixed-citation></ref></ref-list></back><floats-group><fig position="float" id="F1"><label>Figure 1.</label><caption><p id="P56">MWCNT-induced polarization of inflammation in mouse lungs. Adult male C57BL/6J mice were exposed to either vehicle (DM) or MWCNTs (40 &#x003bc;g/mouse adjusted to body weight) via oropharyngeal aspiration. Lung tissue was collected at 1-day and 7-days post-exposure. (A) EM imaging of MWCNTs. The Mitsui-7 MWCNTs are rod-like fibers under TEM at 50,000x magnification. (B) Immunoblotting of M1 (CD68) and M2 (CD206) markers. &#x003b2;-actin was blotted as loading control. (C)-(F) Lung type 1 (TNF-&#x003b1; and IL-1&#x003b2;) and type 2 (IL-4 and IL-13) cytokines quantified by ELISA. Data represents mean &#x000b1; SD from 3 mice each group. Statistical significance is indicated as ns (non-significance), *<italic toggle="yes">p</italic> &#x0003c; 0.05, **<italic toggle="yes">p</italic> &#x0003c; 0.01, ***<italic toggle="yes">p</italic> &#x0003c; 0.001, ****<italic toggle="yes">p</italic> &#x0003c; 0.0001.</p></caption><graphic xlink:href="nihms-2176311-f0001" position="float"/></fig><fig position="float" id="F2"><label>Figure 2.</label><caption><p id="P57">MWCNT-Induced inflammation-to-resolution transition in mouse lungs at 7-days post-exposure. Mice were treated as described in <xref rid="F1" ref-type="fig">Figure 1</xref>. Lung tissue was collected at 7-days post-exposure. Lung sections were stained for neutrophils (A, B; anti-Ly-6G and Ly-6C, red) or macrophages (C, D; anti-Mac2, red) using immunohistochemistry. Red arrows indicate phagocytes in alveolar septa; green arrows indicate phagocytes in the alveolar cavity; and black arrows indicate macrophages containing engulfed MWCNTs. Quantification of neutrophil (E) and macrophage (F) accumulation is shown as mean &#x000b1; SD from samples of four mice in each group. Statistical significance is indicated as ns (non-significance) and ***<italic toggle="yes">p</italic> &#x0003c; 0.001.</p></caption><graphic xlink:href="nihms-2176311-f0002" position="float"/></fig><fig position="float" id="F3"><label>Figure 3.</label><caption><p id="P58">MWCNT-Induced accumulation of phospholipids in macrophages. J774A.1 macrophage cells were cultured in DMEM with 10% FBS overnight and then treated with either vehicle control (A-C) or MWCNTs at 2 &#x003bc;g/mL (D-F) for 24 hours. Following treatment, cells were stained with LTRP for an additional 24 hours and then fixed with 3.7% formaldehyde. DAPI was used to counterstain the nuclei. Images were captured using phase contrast for cell morphology (A, D), a DAPI filter for DAPI fluorescence (B, E), and a TRITC filter for LTRP fluorescence (C, F). Scale bar was set at 200 &#x003bc;m. Quantification of fluorescence intensity is shown in (G)-(K). (L) Illustration of the pathway through which MWCNTs increased phospholipid levels in macrophages, leading to the release of polyunsaturated fatty acids such as AA, DHA, and EPA. Data represent mean &#x000b1; SD from four separate samples. Statistical significance is indicated as ns (non-significance) and ****<italic toggle="yes">p</italic> &#x0003c; 0.0001. RFU: relative fluorescence unit. PLA2, phospholipase A2.</p></caption><graphic xlink:href="nihms-2176311-f0003" position="float"/></fig><fig position="float" id="F4"><label>Figure 4.</label><caption><p id="P59">Induced production of PGs and TXs from arachidonic acid. Lung homogenates from mice treated with either vehicle or MWCNTs were analyzed by UPLC-MS/MS to quantify lipid mediators from the pathways of PG and TX synthesis. (A) Illustration of the production of ILMs through COX-mediated synthesis of PGs and TX from AA. Upward arrows indicate significantly increased lipid mediators. (B-G) Quantification of lipid mediator levels, including AA (B), PGH2 (C), PGE2 (D), PGD2 (E), TXB2 (F), and PGF2&#x003b1; (G). Data represent mean &#x000b1; SD from samples of four mice in each group. Statistical significance is indicated as ns (non-significance) and *<italic toggle="yes">p</italic> &#x0003c; 0.05. Cox, cyclooxygenase; PGDS, prostaglandin D synthase; PGES, prostaglandin E synthase; PGFS, prostaglanding F synthase; and TXS, thromboxane synthase.</p></caption><graphic xlink:href="nihms-2176311-f0004" position="float"/></fig><fig position="float" id="F5"><label>Figure 5.</label><caption><p id="P60">Induced production of LTs and LXs from arachidonic acid. Lung homogenates from mice treated with either vehicle or MWCNTs were analyzed by UPLC-MS/MS to quantify lipid mediators from the pathways of leukotriene and lipoxin synthesis. (A) Illustration of the production of LMs through Alox-mediated synthesis of LTs and LXs from AA. Upward arrows indicate significantly increased lipid mediators. (B-F) Quantification of lipid mediator levels, including LTB4 (B), 5-HETE (C), LXB4 (D), 15-HETE (E), and 12-HETE (F). Data represent mean &#x000b1; SD from samples of four mice in each group. Statistical significance is indicated as ns (non-significance) and *<italic toggle="yes">p</italic> &#x0003c; 0.05; **<italic toggle="yes">p</italic> &#x0003c; 0.01. Alox, arachidonate lipoxygenase.</p></caption><graphic xlink:href="nihms-2176311-f0005" position="float"/></fig><fig position="float" id="F6"><label>Figure 6.</label><caption><p id="P61">Induced production of SPMs from DHA. Lung homogenates from mice treated with either vehicle or MWCNTs were analyzed by UPLC-MS/MS to quantify lipid mediators from the pathways of SPM synthesis from DHA. (A) Illustration of the production of SPMs (RvDs, MaRs, and PDs) from DHA. Upward arrows indicate significantly increased lipid mediators. (B-J) Quantification of SPM levels, including DHA (B), RvD2 (C), RvD3 (D), RvD5 (E), PD1 (F), PDX (G), 17-HDHA (H), MaR1 (I), and 14S-HDHA (J). Data represent mean &#x000b1; SD from samples of four mice in each group. Statistical significance is indicated as ns (non-significance) and *<italic toggle="yes">p</italic> &#x0003c; 0.05; **<italic toggle="yes">p</italic> &#x0003c; 0.01. Alox, arachidonate lipoxygenase.</p></caption><graphic xlink:href="nihms-2176311-f0006" position="float"/></fig><fig position="float" id="F7"><label>Figure 7.</label><caption><p id="P62">Induced production of SPMs from EPA. Lung homogenates from mice treated with either vehicle or MWCNTs were analyzed by UPLC-MS/MS to quantify lipid mediators from the pathways of SPM synthesis from EPA. (A) Illustration of the production of SPMs (RvEs and LXs) from EPA. Upward arrows indicate significantly increased lipid mediators. (B-H) Quantification of SPM levels, including EPA (B), RvE2 (C), 18-HEPE (D), RvE4 (E), 15-HEPE (F), 5-HEPE (G), and 12-HEPE (H). Data represent mean &#x000b1; SD from samples of four mice in each group. Statistical significance is indicated as ns (non-significance) and **<italic toggle="yes">p</italic> &#x0003c; 0.01; ***<italic toggle="yes">p</italic> &#x0003c; 0.001. Alox, arachidonate lipoxygenase; Cox, cyclooxygenase; Cyp, cytochrome P-450.</p></caption><graphic xlink:href="nihms-2176311-f0007" position="float"/></fig></floats-group></article>